Therapy for EGFR tyrosine kinase inhibitor-resistant NSCLC with a focus on the T790M-resistant mutation
Crossref DOI link: https://doi.org/10.1007/s12254-016-0288-y
Published Online: 2016-10-11
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zabernigg, August http://orcid.org/0000-0002-1786-4740
Text and Data Mining valid from 2016-10-11
Article History
Received: 28 August 2016
Accepted: 13 September 2016
First Online: 11 October 2016
Conflict of interest
: A. Zabernigg declares that he has no competing interests.